A longitudinal study of Candida bloodstream infections in a Japanese university hospital: species distribution, drug susceptibility, clinical features, and mortality predictors

Eur J Clin Microbiol Infect Dis. 2022 Nov;41(11):1315-1325. doi: 10.1007/s10096-022-04499-0. Epub 2022 Sep 26.

Abstract

We aimed to detect possible changes in Candida species distribution over time and to know the antifungal susceptibility profile of isolates obtained from patients with bloodstream infection (BSI) due to this pathogen. Risk factors associated with 30-day mortality were also assessed. We conducted a retrospective cohort study of patients diagnosed with Candida BSI at a Japanese university hospital from 2013 to 2021. The change in the distribution pattern of the Candida spp. isolated was examined by considering three successive sub-periods of 3 years each. Risk factors for 30-day mortality were determined using Cox regression analysis. In the entire study period, Candida albicans was the most frequent species (46.7%), followed by Candida glabrata (21.5%) and Candida parapsilosis (18.7%). There was no change in Candida species distribution comparing the three sub-periods analyzed. All isolates were susceptible to micafungin, and most were susceptible to fluconazole, except for C. glabrata. No isolates were resistant to amphotericin B or voriconazole. The overall 30-day mortality was 40.2%. Univariate analysis revealed an association between 30-day mortality and central venous catheter (CVC) removal at any time, high Pitt bacteremia score (PBS), and high Charlson comorbidity index (CCI). Multivariate Cox analysis found that high PBS was the only independent predictor of 30-day mortality; subsequent multivariate Cox regression demonstrated that early CVC removal significantly reduced 30-day mortality. Candida species distribution and antifungal susceptibility profile in our hospital remained similar from 2013 to 2021. Early CVC removal may improve candidemia outcomes.

Keywords: 30-day mortality; Bloodstream infection; Candida spp.; Central venous catheter; Risk factors; Species distribution.

MeSH terms

  • Amphotericin B
  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Candida
  • Candida glabrata
  • Candidemia* / diagnosis
  • Candidemia* / drug therapy
  • Candidemia* / epidemiology
  • Candidiasis* / drug therapy
  • Candidiasis* / epidemiology
  • Drug Resistance, Fungal
  • Fluconazole
  • Hospitals, University
  • Humans
  • Japan / epidemiology
  • Longitudinal Studies
  • Micafungin
  • Microbial Sensitivity Tests
  • Retrospective Studies
  • Voriconazole

Substances

  • Antifungal Agents
  • Amphotericin B
  • Fluconazole
  • Voriconazole
  • Micafungin